Garenoxacin mesylate hydrate
CAS No. 223652-90-2
Garenoxacin mesylate hydrate ( Garenoxacin mesylate [USAN]; BMS-284756-01; Garenoxacin mesylate )
产品货号. M13586 CAS No. 223652-90-2
A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥381 | 有现货 |
|
5MG | ¥527 | 有现货 |
|
10MG | ¥672 | 有现货 |
|
25MG | ¥1288 | 有现货 |
|
50MG | ¥2163 | 有现货 |
|
100MG | ¥3208 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Garenoxacin mesylate hydrate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.
-
产品描述A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.Bacterial Infection Approved
-
同义词Garenoxacin mesylate [USAN]; BMS-284756-01; Garenoxacin mesylate
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体Antibacterial
-
研究领域Infection
-
适应症Bacterial Infection
化学信息
-
CAS Number223652-90-2
-
分子量540.53
-
分子式C24H26F2N2O8S
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 30 mg/mL
-
SMILESC[C@@H]1c2ccc(cc2CN1)c3ccc4c(c3OC(F)F)n(cc(c4=O)C(=O)O)C5CC5.CS(=O)(=O)O.O
-
化学全称3-Quinolinecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-2,3-dihydro-1-methyl-1H-isoindol-5-yl]-1,4-dihydro-4-oxo-, methanesulfonate, hydrate (1:1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Besifloxacin hydroch...
A fourth-generation fluoroquinolone antibiotic that exhibits a broad spectrum in vitro activity against a wide range of Gram-positive and Gram-negative ocular pathogens.
-
1835F03
1835F03 is a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus.
-
PBP 10
Selective formyl peptide receptor 2 (FPR2) antagonist; cell permeable. Selectively inhibits FPR2-mediated NADPH oxidase activity but has no effect on FPR1 signaling in neutrophils. Displays PIP2 binding activity in vitro and blocks cell motility. Also exhibits antiviral activity against influenza viruses via inhibition of viral-induced ERK activation.